QLGN — Qualigen Therapeutics Share Price
0.000.00%
Last trade - 00:00- $2.58m
- $3.62m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 5.65 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
Directors
- Michael Poirier CHM (65)
- Amy Broidrick PRE (63)
- Christopher Lotz CFO (56)
- Shishir Sinha COO (54)
- Tariq Arshad SVP
- Wajdi Abdul-Ahad CSO (68)
- Ira Ritter DRC (72)
- Richard David IND (61)
- Sidney Emery IND (71)
- Matthew Korenberg IND (46)
- Kurt Kruger IND (65)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- September 16th, 2008
- Public Since
- June 24th, 2015
- No. of Shareholders
- 287
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 736,431
- Address
- 2042 Corte Del Nogal, CARLSBAD, 92011
- Web
- https://qlgntx.com/
- Phone
- +1 7609189165
- Auditors
- BAKER TILLY US LLP
Upcoming Events for QLGN
Q2 2025 Qualigen Therapeutics Inc Earnings Release
Qualigen Therapeutics Inc Annual Shareholders Meeting
Similar to QLGN
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Qualigen Therapeutics share price?
As of Today at 22:49 UTC, shares in Qualigen Therapeutics are trading at $3.50. This share price information is delayed by 15 minutes.
How has the Qualigen Therapeutics share price performed this year?
Shares in Qualigen Therapeutics last closed at $3.50 and the price had moved by -75.89% over the past 365 days. In terms of relative price strength the Qualigen Therapeutics share price has underperformed the S&P500 Index by -78.26% over the past year.
What are the analyst and broker recommendations for Qualigen Therapeutics?
The overall consensus recommendation for Qualigen Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Qualigen Therapeutics dividend yield?
Qualigen Therapeutics does not currently pay a dividend.
Does Qualigen Therapeutics pay a dividend?
Qualigen Therapeutics does not currently pay a dividend.
When does Qualigen Therapeutics next pay dividends?
Qualigen Therapeutics does not currently pay a dividend.
How do I buy Qualigen Therapeutics shares?
To buy shares in Qualigen Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Qualigen Therapeutics?
As of the previous close price of $3.50, shares in Qualigen Therapeutics had a market capitalisation of $2.58m.
Where are Qualigen Therapeutics shares listed?
Here are the trading details for Qualigen Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: QLGN
What kind of share is Qualigen Therapeutics?
Based on an overall assessment of its quality, value and momentum Qualigen Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Qualigen Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Qualigen Therapeutics is $5.00. That is 42.86% above the last closing price of $3.50.
Analysts covering Qualigen Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.00 for the next financial year.
Find out moreWhat is the trend in the Qualigen Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Qualigen Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -28.54%.
As of the last closing price of $3.50, shares in Qualigen Therapeutics were trading -40.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Qualigen Therapeutics PE Ratio?
The Qualigen Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Qualigen Therapeutics?
Qualigen Therapeutics' management team is headed by:
- Michael Poirier - CHM
- Amy Broidrick - PRE
- Christopher Lotz - CFO
- Shishir Sinha - COO
- Tariq Arshad - SVP
- Wajdi Abdul-Ahad - CSO
- Ira Ritter - DRC
- Richard David - IND
- Sidney Emery - IND
- Matthew Korenberg - IND
- Kurt Kruger - IND